Monday, October 22, 2018
News
NEWS HOME
»
PRN INDIA
Merck Data at ESMO 2018 Congress Highlight Multiple Therapeutics with Potential to Transform Cancer Care
  SocialTwist Tell-a-Friend  
   

DARMSTADT, Germany, October 9, 2018 /PRNewswire/ --

Not intended for distribution in the USA, Canada or UK  

ESMO Abstract #

Avelumab: LBA6_PR, 659P, 1290P, 1291P, 1282P, 877P; M7824 (TGF β-trap/anti-PD-L1):1048O, 1463P, 1931P, 757P, 643P, 642P, 661P; tepotinib (MET kinase inhibitor): 1377O, 621PD, 698P; M6620: 1437P; M3814: 1845P; M7583: 1014PD; abituzumab: 487P; Erbitux ®(cetuximab): 124P, 484P, 509P, 493P, 521P, 510P, 481P, 486P, 1057P, 1108P, 1068P, 1064P, 1293P

  • First presentation of Phase III data for avelumab (plus axitinib) in previously untreated, advanced kidney cancer
  • New and updated data for bifunctional immunotherapy M7824  
  • Results from Phase II trials for tepotinib, including in EGFR TKI-resistant NSCLC  
  • Additional pipeline data feature abstracts for a further four innovative agents across multiple tumor types with a significant patient need  

Merck, a leading science and technology company, today announced that new data from a variety of high-priority clinical development programs will be presented at the ESMO 2018 Congress (European Society for Medical Oncology Annual Meeting), October 19-23, 2018, Munich, Germany.

In the year that Merck celebrates its 350-year anniversary, abstracts at the congress represent a company record with eight therapeutic agents across 14 tumor types, reinforcing Merck's position at the forefront of clinical development in oncology.

"Our data at this year's European Society for Medical Oncology Congress expand our understanding of avelumab in renal cell carcinoma and other tumors, and demonstrate the headway we are making with our pipeline, including bifunctional immunotherapy M7824 and tepotinib," said Luciano Rossetti, Global Head of Research & Development for the Biopharma business of Merck. "We look forward to many more years of real and significant progress towards our vision of transforming the management and treatment of cancer."

Data from the Phase III study JAVELIN Renal 101, evaluating avelumab* in combination with axitinib, compared with sunitinib as initial therapy for patients with advanced renal cell carcinoma (RCC), will be presented for the first time during the Presidential Symposium at ESMO on Sunday, October 21, 2018 at 5:20 PM - 5:35 PM CEST. Avelumab is being jointly developed and commercialized with Pfizer. The results represent the first positive Phase III immunotherapy trial in combination with a tyrosine kinase inhibitor (TKI) in any tumor type, supporting Merck's interest in the potential use of avelumab in combination with currently approved therapies and novel agents. These results will be submitted for publication in a peer-reviewed journal. Other updates include new avelumab data in Merkel cell carcinoma (MCC) and advanced gastric or gastroesophageal junction (GEJ) cancer.

New data for M7824 will be presented from expansion cohorts of two ongoing Phase I clinical trials, including the first tumor-specific data for squamous cell carcinoma of the head and neck (SCCHN), biliary tract cancer, esophageal squamous cell carcinoma and esophageal adenocarcinoma. In addition, updated data for M7824 in patients with gastric cancer and non-small cell lung cancer (NSCLC) will be shared. M7824, discovered in-house at Merck, is an investigational bifunctional immunotherapy designed to combine a transforming growth factor β (TGF-β) trap by 'fusing' it with the anti-programmed death ligand-1 (PD-L1) mechanism. To date more than 650 patients with various types of solid tumors have been treated across the program with M7824 and the safety profile is consistent with that observed with other PD-1/PD-L1 inhibitors and previously described skin lesions (keratoacanthomas, SCC, hyperkeratosis) associated with TGF-β-inhibiting therapies.

Data for tepotinib** include results from three Phase II trials in epidermal growth factor receptor (EGFR) TKI-resistant NSCLC and advanced hepatocellular carcinoma, providing further evidence of this precision medicine's potential clinical activity in a range of tumors. Tepotinib, discovered in-house at Merck, is an investigational, oral MET inhibitor that is designed to selectively inhibit the oncogenic MET receptor signaling caused by MET (gene) alterations or MET protein overexpression.

Additional pipeline abstracts feature updated data from Merck's comprehensive DNA damage response (DDR) portfolio. These include results from a Phase I trial investigating M6620 (formerly VX-970) in combination with gemcitabine in patients with advanced NSCLC, and combined data from two Phase I trials of DNA-dependent protein kinase inhibitor, M3814. Results will also be shared from a Phase I/II trial of M7583, a Bruton's TKI, in patients with B-cell malignancies, as well as a retrospective analysis of the Phase I/II Poseidon study investigating abituzumab in patients with metastatic colorectal cancer (mCRC).

Data to be presented at the congress for Erbitux ® will add to the growing body of real-world evidence supporting the therapy's role as a standard of care in RAS wild-type mCRC and first-line recurrent or metastatic SCCHN (R/M SCCHN), and for patients with locally advanced SCCHN (LA SCCHN) who may not be able to tolerate cisplatin-based regimens in full.  

*Avelumab is under clinical investigation for the treatment of RCC, MCC, CRC, gastric and GEJ cancer, and has not been demonstrated to be safe and effective for these indications. There is no guarantee that avelumab will be approved for RCC, CRC, gastric or GEJ cancer by any health authority worldwide.

**Tepotinib is the recommended International Nonproprietary Name (INN) for the MET kinase inhibitor MSC2156119J. Tepotinib is currently under clinical investigation and not approved for any use anywhere in the world.

Tepotinib, M7824, M3814, M7583, M6620 and abituzumab are under clinical investigation and have not been proven to be safe and effective. There is no guarantee any product will be approved in the sought-after indication by any health authority worldwide.

Notes to Editors  

Key Merck-supported abstracts slated for presentation are listed below. In addition, a number of investigator-sponsored studies have been accepted (not listed).


   
    Title                   Lead Author   Abstract #  Presentation       Location

                                                      Date / Time
                                                      (CEST)
    Avelumab
    Late-Breaking Abstracts
    JAVELIN Renal 101:      R Motzer      LBA6_PR     Sun, Oct 21,       Hall A2 -
    a randomized,                                     4:30 - 6:10 PM     Room 18
    phase 3 study of                                  (5:20 - 5:35 PM
    avelumab +                                        lecture time)
    axitinib vs                                      
    sunitinib as
    first-line
    treatment of
    advanced renal
    cell carcinoma                        
    (aRCC)    

    Poster Sessions
    Avelumab                T Doi         659P        Sun, Oct 21        Hall A3 -
    (anti-PD-L1) in                                   12:45 - 1:45 PM    Poster Area
    Japanese patients                                                    Networking Hub
    with advanced
    gastric or
    gastroesophageal
    junction cancer
    (GC/GEJC): updated
    results from the              
    phase 1b JAVELIN                                      
    Solid Tumor JPN                              
    trial                 
    Avelumab in             P Nathan      1290P       Sun, Oct 21,       Hall A3 -
    European patients                                 12:45 - 1:45 PM    Poster Area
    (pts) with                                                           Networking Hub
    metastatic Merkel
    cell carcinoma
    (mMCC): experience                       
    from an ad hoc                                        
    expanded access                         
    program (EAP)
    Cost-effectiveness      M Bharmal     1291P       Sun, Oct 21,       Hall A3 -
    (CE) of avelumab                                  12:45 - 1:45 PM    Poster Area
    vs standard care                                                     Networking Hub
    (SC) for the
    treatment of
    patients (pts)
    with metastatic                                           
    Merkel cell                                
    carcinoma (mMCC)  
    Responder analysis      SP D'Angelo   1282P       Sun, Oct 21,       Hall A3 -
    based on                                          12:45 - 1:45 PM    Poster Area
    patient-reported                                                     Networking Hub
    outcomes (PROs)
    and clinical
    endpoints (CEPs)
    in patients (pts)
    with metastatic
    Merkel cell                                     
    carcinoma (mMCC)                                        
    treated with                               
    avelumab          
    First-line (1L) or      UN                        Mon, Oct 22,       Hall A3 -
    second-line (2L)        Vaishampayan  877P        12:45 - 1:45 PM    Poster Area
    avelumab                                                             Networking Hub
    monotherapy in
    patients (pts)
    with advanced
    renal cell
    carcinoma (aRCC)
    enrolled in the 
    phase 1b JAVELIN 
    Solid Tumor trial 


   
    Title                         Lead Author   Abstract #  Presentation      Location
                                                            Date / Time
                                                            (CEST
    M7824 (TGF β-trap/anti-PD-L1)

    Proffered Paper Session
    M7824                         BC Cho        1048O       Mon, Oct 22,      ICM, Room
    (MSB0011359C), a                                        2:45 - 4:15 PM    14B
    bifunctional                                            (3:00 PM
    fusion protein                                          lecture time)
    targeting PD-L1
    and TGF-β, in
    patients (pts)
    with advanced                            
    SCCHN: results                                  
    from a phase 1                                   
    cohort                       
    Poster Sessions
    Updated results of            L Paz-Ares    1463P       Sat, Oct 20,      Hall A3 -
    M7824                                                   12:30 - 1:30 PM   Poster Area
    (MSB0011359C), a                                                          Networking Hub
    bifunctional
    fusion protein
    targeting TGF-β                                               
    and PD-L1, in                                                           
    second-line (2L)                                        
    NSCLC             
    Assessment of PD1/            T Mrowiec     1931P       Sun, Oct 21,      Hall A3 -
    PD-L1                                                   12:45 - 1:45 PM   Poster Area
    colocalization in                                                         Networking Hub
    hepatocellular
    carcinoma (HCC)
    using brightfield
    double labeling                            
    and quantitative                                 
    digital image                      
    analysis         
    M7824                         C Yoo         757P        Sun, Oct 21,      Hall A3 -
    (MSB0011359C), a                                        12:45 - 1:45 PM   Poster Area
    bifunctional                                                              Networking Hub
    fusion protein
    targeting PD-L1
    and TGF-β, in
    Asian patients
    with pretreated
    biliary tract
    cancer:  
    preliminary                                           
    results from a                         
    phase 1 trial     
    M7824                         B Tan          643P       Sun, Oct 21,      Hall A3 -
    (MSB0011359C), a                                        12:45 - 1:45 PM   Poster Area
    bifunctional                                                              Networking Hub
    fusion protein
    targeting PD-L1
    and TGF-β, in
    patients with
    post-platinum
    esophageal
    adenocarcinoma                                 
    (EAC): preliminary                                      
    results from a                            
    phase 1 cohort     
    Phase 1 study                 CC Lin         642P       Sun, Oct 21,      Hall A3 -
    results from an                                         12:45 - 1:45 PM   Poster Area
    esophageal                                                                Networking Hub
    squamous cell
    carcinoma (ESCC)
    cohort treated
    with M7824
    (MSB0011359C), a
    bifunctional
    fusion protein
    targeting
    transforming                                
    growth factor β                                     
    (TGF-β) and                           
    PD-L1             
    Updated results               YJ Bang        661P       Sun, Oct 21,      Hall A3 -
    from a phase 1                                          12:45 - 1:45 PM   Poster Area
    trial of M7824                                                            Networking Hub
    (MSB0011359C), a
    bifunctional
    fusion protein
    targeting PD-L1
    and TGF-β, in
    patients with                 
    pretreated                                            
    recurrent or                                           
    refractory gastric                                
    cancer            


   
    Title                   Lead Author  Abstract #  Presentation      Location
                                                     Date / Time
                                                     (CEST)
    Tepotinib
    Proffered Paper Session
    Phase 2 study of        YL Wu        1377O       Fri, Oct 19,      Hall A2,
    tepotinib +                                      4:00 - 5:30 PM    Room 18
    gefitinib                                        (4:51 PM
    (TEP+GEF) in                                     lecture time)
    MET-positive
    (MET+)/epidermal
    growth factor
    receptor                           
    (EGFR)-mutant (MT)                   
    non-small lung                           
    cancer (NSCLC)   
    Poster Discussion
    Phase 2 trial of         BY Ryoo     621PD       Fri, Oct 19,      Hall B3,
    tepotinib vs                                     3:45 - 5:30 PM    Room 21
    sorafenib in Asian                               (4:25 PM
    patients (pts)                                   lecture time)
    with advanced                            
    hepatocellular                            
    carcinoma (HCC)  
    Poster Session
    Phase 2 efficacy         T Decaens   698P        Sun, Oct 21,      Hall A3 -
    and safety data                                  12:45 - 1:45 PM   Poster Area
    for the MET                                                        Networking Hub
    inhibitor
    tepotinib in
    patients (pts)
    with                                  
    sorafenib-treated                                  
    advanced                                                
    hepatocellular                                          
    carcinoma (HCC)   


   
    Title              Lead Author  Abstract #  Presentation     Location
                                                Date / Time
                                                (CEST)         
    M6620
    Poster Session
    Phase I dose       R Plummer    1437P       Sat, Oct 20,     Hall A3 -
    expansion data for                          12:30 - 1:30 PM  Poster Area
    M6620 (formerly                                              Networking Hub
    VX-970), a
    first-in-class ATR
    inhibitor,
    combined with
    gemcitabine (Gem)
    in patients (pts)
    with advanced   
    non-small cell 
    lung cancer                           
    (NSCLC)     


   
    Title              Lead Author     Abstract #  Presentation     Location
                                                   Date / Time
                                                   (CEST)
    M3814
    Poster Session
    Safety, clinical   M Mau-Sørensen  1845P       Sat, Oct 20,     Hall A3 -
    activity and                                   12:30 - 1:30 PM  Poster Area
    pharmacological                                                 Networking Hub
    biomarker
    evaluation of the
    DNA-dependent
    protein kinase
    (DNAPK) inhibitor
    M3814: results                                           
    from two phase I  
    trials              


   
    Title              Lead Author   Abstract #  Presentation    Location
                                                 Date / Time
                                                 (CEST)
    M7583
    Poster Session
    Phase I/II, first  W Jurczak     1014PD      Sun, Oct 21,    Hall B3 -
    in human trial                               4:30 - 5:45 PM  Room 21
    with M7583, a
    Bruton's tyrosine
    kinase inhibitor
    (BTKi), in
    patients with B
    cell malignancies      



   
    Title              Lead Author   Abstract #  Presentation      Location
                                                 Date / Time
                                                 (CEST)
    Abituzumab
    Poster session
    Patient selection   R Laeufle    487P        Sun, Oct 21,      Hall A3 -
    for targeting                                12:45 - 1:45 PM   Poster Area
    integrin with                                                  Networking Hub
    abituzumab in
    patients with
    metastatic
    colorectal cancer
    (mCRC). A
    retrospective
    analysis of the                                      
    randomized phase                                        
    I/II Poseidon                            
    study            


   
    Title              Lead Author        Abstract #  Presentation       Location
                                                      Date / Time
                                                      (CEST)  
    Erbitux
    Poster Sessions
    Association of     L Miller-Phillips  124P        Sat, Oct 20,       Hall A3 -
    microRNA-21                                       12:30 - 1:30 PM    Poster Area
    (miR-21) with                                                        Networking Hub
    efficacy of
    cetuximab (cet)
    and bevacizumab
    (bev) in patients
    with metastatic
    colorectal cancer                                    
    (mCRC) within the
    FIRE-3 study (AIO 
    KRK-0306)         
    Retrospective RAS   A Sobrero         484P        Sun, Oct 21,       Hall A3 -
    analysis of the                                   12:45 - 1:45 PM    Poster Area
    EPIC trial:                                                          Networking Hub
    Cetuximab plus
    irinotecan versus
    irinotecan alone
    in patients with
    third- and                           
    further-line                                           
    metastatic                                
    colorectal cancer
    Factors             DP Modest         509P        Sun, Oct 21,       Hall A3 -
    influencing                                       12:45 - 1:45 PM    Poster Area
    conversion to                                                        Networking Hub
    resectability and
    survival after
    resection of
    metastases in RAS
    WT metastatic
    colorectal cancer                                      
    (mCRC): analysis                                           
    of FIRE-3-                                  
    AIOKRK0306        
    Initial report of   E Oki             493P        Sun, Oct 21,       Hall A3 -
    a phase I/II study                                12:45 - 1:45 PM    Poster Area
    of S-1 and                                                           Networking Hub
    irinotecan (IRIS)
    in combination
    with cetuximab in
    patients with                                          
    wild-type (wt) RAS                                         
    metastatic                            
    colorectal cancer 
    miR-31 as a         Y Gaston-Mathé    521P        Sun, Oct 21,       Hall A3 -
    prognostic and                                    12:45 - 1:45 PM    Poster Area
    predictive marker                                                    Networking Hub
    of disease-free
    survival (DFS) in
    resected stage III
    colon cancer: a                             
    retrospective                                           
    analysis of the  
    PETACC-8 trial    
    Targeted therapies  BC Xing           510P        Sun, Oct 21,       Hall A3 -
    in conversion                                     12:45 - 1:45 PM    Poster Area
    therapy in mCRC: A                                                   Networking Hub
    systematic review 
    and meta-analysis 
    Phase II study of   H Osawa           481P        Sun, Oct 21,       Hall A3 -
    cetuximab                                         12:45 - 1:45 PM    Poster Area
    rechallenge in                                                       Networking Hub
    patients with RAS
    wild-type
    metastatic          
    colorectal cancer:                               
    E-rechallenge           
    trial            
    Prospective         X García-Albéniz  486P        Sun, Oct 21,       Hall A3 -
    biomarker study in                                12:45 - 1:45 PM    Poster Area
    advanced RAS                                                         Networking Hub
    wild-type                   
    colorectal cancer.
    POSIBA trial.     
    (GEMCAD 10-02)    
    Cetuximab +         C Le Tourneau     1057P       Sun, Oct 21,       Hall A3 -
    platinum-based                                    12:45 - 1:45 PM    Poster Area
    therapy (PBT) as a                                                   Networking Hub
    first-line
    treatment for
    patients with
    recurrent/metastat
    ic squamous cell
    carcinoma of the
    head and neck (R/M                                            
    SCCHN): an                                                        
    observational                                      
    study (ENCORE)      
    Can concomitant     J Dunst           1108P        Sun, Oct 21,      Hall A3 -    
    diseases predict                                   12:45 - 1:45 PM   Poster Area
    the compliance                                                       Networking Hub
    with cisplatin
    plus RT in
    patients with
    locally advanced
    squamous cell
    carcinoma of the
    head and neck (LA
    SCCHN)? An
    exploratory                                       
    endpoint analysis                                    
    of the COMPLY                               
    trial             
    Cetuximab in        JC Ham            1068P        Sun, Oct 21,      Hall A3 -
    combination with                                   12:45 - 1:45 PM   Poster Area
    methotrexate (MTX)                                                   Networking Hub
    as first-line
    treatment in
    recurrent or
    metastatic (R/M)
    squamous cell
    carcinoma of the
    head and neck
    (SCCHN), a phase
    Ib - randomized                                    
    phase II study                                        
    versus single                               
    agent MTX         
    Cetuximab in        M Hecht           1064P         Sun, Oct 21,     Hall A3 -  
    combination with                                    12:45 - 1:45 PM  Poster Area
    platinum-based                                                       Networking Hub
    chemotherapy or
    radiotherapy in
    patients with
    recurrent and/or
    metastatic SSCHN
    in clinical
    routine: Updated                                    
    interim results of                                        
    the prospective                             
    SOCCER study      
    Cetuximab in        F Peyrade         1293P          Sun, Oct 21,    Hall A3 -
    patients with                                        12:45 - 1:45 PM Poster Area
    unresectable                                                         Networking Hu
    cutaneous squamous
    cell carcinoma is                                    
    safe and effective                                    
    - A real-life                               
    analysis         

About Avelumab  

Avelumab is a human anti-programmed death ligand-1 (PD-L1) antibody. Avelumab has been shown in preclinical models to engage both the adaptive and innate immune functions. By blocking the interaction of PD-L1 with PD-1 receptors, avelumab has been shown to release the suppression of the T cell-mediated antitumor immune response in preclinical models.[1]-[3] Avelumab has also been shown to induce NK cell-mediated direct tumor cell lysis via antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro.[3]-[5] In November 2014, Merck and Pfizer announced a strategic alliance to co-develop and co-commercialize avelumab.

Avelumab is currently being evaluated in the JAVELIN clinical development program, which involves at least 30 clinical programs, including seven Phase III trials, and more than 8,600 patients across more than 15 different tumor types. For a comprehensive list of all avelumab trials, please visit clinicaltrials.gov.

Approved Indications in the US  

The US Food and Drug Administration (FDA) granted accelerated approval for avelumab (BAVENCIO ®) for the treatment of (i) adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (mMCC) and (ii) patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12  months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. These indications are approved under accelerated approval based on tumor response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.

Important Safety Information from the US FDA Approved Label  

The warnings and precautions for BAVENCIO include immune-mediated adverse reactions (such as pneumonitis, hepatitis, colitis, endocrinopathies, nephritis and renal dysfunction, and other adverse reactions), infusion-related reactions and embryo-fetal toxicity.

Common adverse reactions (reported in at least 20% of patients) in patients treated with BAVENCIO for mMCC and patients with locally advanced or mUC include fatigue, musculoskeletal pain, diarrhea, nausea, infusion-related reaction, peripheral edema, decreased appetite/hypophagia, urinary tract infection and rash.

About M7824  

M7824 is an investigational bifunctional immunotherapy that is designed to bring together a TGF-β trap and 'fuse' it with the anti-PD-L1 mechanism. M7824 is designed to simultaneously block the two immunosuppressive pathways - targeting both pathways aims to control tumor growth by potentially restoring and enhancing anti-tumor responses. M7824 is currently in Phase I studies for solid tumors.

About Tepotinib  

Tepotinib (MSC2156119J) is an investigational, oral MET inhibitor that is thought to inhibit oncogenic MET receptor signaling caused by MET (gene) alterations, including both MET exon 14 skipping mutations and MET amplifications, or MET protein overexpression. It is a precision medicine and is designed to have a highly selective mechanism of action.

About M6620  

M6620 (previously known as VX-970) is an investigational small-molecule thought to inhibit ataxia telangiectasia and Rad3-related protein (ATR). ATR is believed to be a key sensor for DNA damage, activating the DNA damage checkpoint and leading to cell cycle arrest. Inhibition of ATR could potentially enhance the efficacy of DNA-damaging agents, but is also being investigated as a monotherapy against tumors with high levels of replication stress induced by overexpression of oncogenes.

About M3814  

M3814 is an investigational small-molecule which is thought to inhibit DNA-dependent protein kinase (DNA-PK). DNA-PK is a key enzyme for non-homologous end-joining (NHEJ), an important DNA double-strand break (DSB) repair pathway. Clinical studies investigating combinations of M3814 with other commonly used DNA-damaging agents such as radiotherapy and chemotherapy are underway.

About M7583  

M7583 is an investigational therapy that is thought to be a highly selective covalent inhibitor of Bruton's tyrosine kinase (BTKi) designed to minimize off-target effects.

About Abituzumab  

Abituzumab is an investigational pan-αν integrin inhibiting monoclonal antibody thought to show activity against αvβ1, 3, 5, 6 and 8 integrin heterodimers. Merck entered into a development agreement with the SFJ Pharmaceuticals Group for abituzumab in metastatic colorectal cancer (mCRC). This collaboration will allow Merck and SFJ to develop the potential of abituzumab in a targeted way, focusing on a patient population that may benefit from the treatment the most.

About Erbitux ® (cetuximab)  

Erbitux ® is a IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). As a monoclonal antibody, the mode of action of Erbitux is distinct from standard non-selective chemotherapy treatments in that it specifically targets and binds to the EGFR. This binding inhibits the activation of the receptor and the subsequent signal-transduction pathway, which results in reducing both the invasion of normal tissues by tumor cells and the spread of tumors to new sites. It is also believed to inhibit the ability of tumor cells to repair the damage caused by chemotherapy and radiotherapy and to inhibit the formation of new blood vessels inside tumors, which appears to lead to an overall suppression of tumor growth. Based on in vitro evidence, Erbitux also targets cytotoxic immune effector cells towards EGFR expressing tumor cells (antibody dependent cell-mediated cytotoxicity, ADCC).

The most commonly reported side effect with Erbitux is an acne-like skin rash. In approximately 5% of patients, hypersensitivity reactions may occur during treatment with Erbitux; about half of these reactions are severe.

Erbitux has already obtained market authorization in over 100 countries world-wide for the treatment of RAS wild-type metastatic colorectal cancer and for the treatment of squamous cell carcinoma of the head and neck (SCCHN). Merck licensed the right to market Erbitux, a registered trademark of ImClone LLC, outside the U.S. and Canada from ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company, in 1998.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck  

Merck is a leading science and technology company in healthcare, life science and performance materials. Almost 53,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck generated sales of € 15.3 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

References  

  1. Dolan DE, Gupta S. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. Cancer Control 2014;21:231-7.
  2. Dahan R et al. FcγRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell 2015;28:285-95.
  3. Boyerinas B et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res 2015;3:1148-57.
  4. Kohrt HE et al. Combination strategies to enhance antitumor ADCC. Immunotherapy 2012;4:511-27.
  5. Hamilton G, Rath B. Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity. Expert Opin Biol Ther 2017;17:515-23.

        (Logo: https://mma.prnewswire.com/media/765882/Merck_Logo.jpg )

More News by PR Newswire India

Tejas Networks Wins Rs. 111 Crore Order for Indian Navy's Communication Network From Sterlite Technologies Limited

DLT Labs™ Launches Universal Access to Blockchain Functionality with New Product: DL Gateway™

$2 Billion in Sight: US Lottery Breaks Record

China's Largest Gifts & Home Fair Opens at Shenzhen Convention & Exhibition Center with 2,500 Exhibitors

Gen Z As Customers: The Unique Needs Of This Generation

Frost & Sullivan Briefing Explores the Impact of Brexit on the UK Economy and Industry

Upgraded Smart Home Appliances and New Energy Products Take Centre Stage at Phase 1 of the Canton Fair

Data is at the Helm of Every Business - WPP India's 'Date with Data' Summit Highlights the Impact and Influence of Data

Tez Financial Services Becomes the First Pakistani Startup to Raise $1.1 Million in Seed Round Led by Omidyar Network

Shaanxi's Xixian New Area Project Explores Innovative Model of Urban Development

Ministry of Tourism of Republic of Indonesia Enters into Two Tourism Cooperation Agreements with Brand Expedia to Promote 15 Key Travel Destinations in Indonesia

Transport and Logistics Sector Emerges as Leader in APAC IoT Technologies Adoption and Spend, says Frost & Sullivan

Don't Miss the Signs of a Breaking Spine, Warns IOF

Menarini Progresses Into the Clinic With MEN1611, a PI3K Inhibitor for the Treatment of HER2 Positive Metastatic Breast Cancer

Siemon at the Forefront of Emerging Single-Pair Ethernet

UnionPay cards issued outside mainland China exceeds 100 million

Discover Why Medical Marijuana Has Healthcare Companies Scrambling to Invest in the $10 Billion-dollar Opportunity

Cruzio and One Wheel/Future Motion - High Tech in Surf City

Dubai Offers Highest Potential Price Growth on Residential Property for Investors Worldwide, According to Emaar

Millionaires Made Online: Uplive India Revolutionizing Real-time Entertainment Economy - Launches in Seven Local Languages

GuardKnox Earns Accolade for its Vehicle Cybersecurity Framework at Frost & Sullivan's 2018 Excellence in Best Practices Award Banquet

Elior India wins the 'Most Innovative Product/Service' Award at the Indo-French Business Awards 2018

Merck Announces Agreement to Sell Amnis® Flow Cytometry and Guava® Technologies Businesses to Luminex Corporation

Sims Recycling Solutions Listed Again as a Representative Vendor in Gartner's "Market Guide for IT Asset Disposition (ITAD)"

Committed to Support China's Belt and Road Initiative, XCMG Wins Big in International Market

Zoya Celebrates Iconic Hollywood Glamour With its New Collection '6299 HOLLYWOOD BLVD'

FISCO BCOS: Challenging Hyperledger Fabric with a Consortium Chain from China

Family Of Missing British Journalist Appeal For Help 9 Years On

Huajuchen Industry Group hosts the 6th Global Tea Fair Xi'an, the best tea fair in western China

Global Tech Firm Abakus Acquires IDX-Listed DEFI

Research into the scaly anteater genome could provide clues to human immunity

Standard Chartered and Huawei Partner to Develop Internet of Things Solution to Expand Ecosystem Lending

Final Two Weeks To Apply For New Awards Totaling $600,000 To Recognize & Support Sustainable Livelihood Programs In Asia, Africa and Latin America

Aerospace Component Manufacturer Arrowhead Products and STS Component Solutions Announce New Distribution Partnership

Stars of Science Presents Its Top Nine Innovators

Cyient reports a strong quarter with Well-rounded growth in Revenue, profit and cash

Vectra Earns Accolade from Frost & Sullivan for its AI-powered Cognito Cybersecurity Platform

PGNiG and Venture Global LNG Announce LNG Sales and Purchase Agreements for 2 Million Tonnes Per Year

Eigen Innovations Commended by Frost & Sullivan for its Unique AI-enabled IoT Solution for Manufacturing

Bitcoin SV version 0.1 goes live

Merck Inaugurates State-of-the-art Pharma Packaging Center in Darmstadt

The 124th Canton Fair to Further Open Chinese Market to Global Buyers

A Higher Intelligence: Huawei Unveils HUAWEI Mate 20 Series

Huawei Releases High-Accuracy Wireless Location Solutions to Simplify Business Digitalization

Top National and International Players Gear-up to Compete at The HCL Asian Junior Tennis Championship 2018

NIIT Technologies Q2 FY2019 PAT up 66.3% YoY

The John Walker Masters' Edition: The First 50 Year Old Scotch Whisky in the History of Johnnie Walker

Codewise Names Dr. John Malatesta Chief Executive Officer

Aeronutrix Sports Products Pvt Ltd Announces Soorma Sandeep Singh as Their Brand Ambassador for Fast&Up

The International E-Business Expo 2018, a nationally celebrated e-commerce expo, will be held in Hangzhou, China in October

Next Story Group Plans 50 Kafnu Properties in Asia Pacific

Pine Labs Enables Debit Card EMIs From HDFC Bank and Axis Bank in Retail Stores

Aspect Software Announces Cloud Offering Aspect Via 18.1 With Smarter Omni-channel Automation, Streamlined Performance Insights, Improved Employee Engagement, GDPR Compliance Capabilities

Treebo Hotels Partners With PhonePe for In-app Hotel Bookings

Deputy CM Sushil Kumar Modi Inaugurated Dandiya Night Organized by Advantage Media

Aidemy is offering an Online Learning Platform Specialising in Blockchain Programming

Oracle's AI Powered Cloud Services Help accelerate digital transformation for Great Human Software

UPDATED -- JHL Biotech Announces China Approves Phase I and Phase III Clinical Trial Application for Bevacizumab Biosimilar to Treat Cancer

D-Link Ethernet Surge Protectors Beat Competitors in Surge Test

High GDP Per Capita and World-class Infrastructure Drive Added Value for Property Investment in Dubai’s Premier Destinations According to Emaar

Fortinet Commended by Frost & Sullivan for Protecting the Entire Attack Surface with its FortiSandbox Line of Cybersecurity Solutions

'The Chronicles of Wizardry' a Book by Four 12 years Olds - Four Students of EuroSchool Whitefield Publish a Book on Amazon

CyberScout To Provide Identity Theft Resolution To Länsförsäkringar; Partnership Will Help SMEs Manage Global Cyber Risks Post GDPR

Apergy Earns Acclaim from Frost & Sullivan for Offering a Full Range of Wellsite Lifecycle Solutions for the Oil and Gas Industry

Mandarin Orchard Singapore bags second win as Best Upscale Hotel-Asia Pacific at the Travel Weekly Asia 2018 Readers' Choice Awards

Largest Skatepark In The Midwest Breaks Ground In Greater Des Moines

AutomationEdge Wins NASSCOM Customer Excellence Award for Delivering Innovation at ICICI Lombard

Jet Midwest Corporate Aviation Launches at NBAA 2018

Ste Industries Commended by Frost & Sullivan for its Micro.sp®, a Cloud-enabled Tire Pressure Monitoring System

Ezetap's Sanjeeb Kalita Joins Innoviti as Chief Revenue Officer

TiE Delhi - NCR and QGLUE Announce the 2nd Edition of India's First Design-led Entrepreneurship Awards

Chitkara University in Collaboration With Association for Computing Machinery (ACM), India Organized COMPUTE 2018

Pason Power Enables Solar and Energy Storage Project Developers to Deploy with Confidence

China's 100 most innovative companies in 2018 named in third annual report by Clarivate Analytics

Honor Launches Honor 8X - The Most Remarkable High Performance Smartphone in India

Acoosta Innovations Launches Acoosta Uno, the World's First Music System With the Largest Variety of Built-in Music in Association With Sony DADC

Aeroflot Flies Off With First-ever Business Traveller Award

Trina Solar Supplies Modules to Ukraine's Largest Solar Power Plant

CLAT Possible Launches its New Centre in Chandigarh

International Athlete in City to Raise Awareness at Key Paediatric Diabetes Forum

Kinshuk Apoorv Agrawal of GIIS Chinchwad Awarded as the 'Women of the Future'

Geopolitical Instability and the Need to Refresh Obsolete Fleets will Drive Recovery of Military and Public Services Helicopters Market

TECNO Launches 'HarSuratKhoobsurat' Brand Campaign for the New CAMON AI Series

TUV India Growth Journey Continues With New Office at Bangalore

UniStrong is now a 42Gears OEM Partner

Hertz Asia Wins Travel Weekly Asia Readers' Choice Awards for the Fourth Consecutive Year

Tapps Enters Indian Footwear Industry to Redefine the Affordable Loafers Segment

TUV Rheinland's Gurgaon, India, product testing lab is now recognised by Telecommunication Engineering Center (TEC), Government of India

Water Scarcity: A Major Threat to Data Centre Reliability and Growth

Ultiloc Copolymers Expand Selvol Functionality

IBM Introduces AI OpenScale to Spur Artificial Intelligence Adoption and Transparency

IBM Unveils World's First Multicloud Management Technology

IBM Announces Cloud-Based Community Platform for Cyber Security Applications

First-ever QS Ranking of India's Higher Education Institutions

CIVCO Radiotherapy Announces FDA 510k Clearance and CE Mark of their Solstice SRS Immobilization System

ORGANO Expands Africa Footprint into South Africa

Updated Breast Cancer Resources and Events from NCCN Keep Patients and Doctors Worldwide Informed during Breast Cancer Awareness Month

Global Artists Gather for Fifth Silk Road International Film Festival Which Marks 60 Years of Film Making at the Iconic Xi'an Film Studio

JHL Biotech Announces China Approves Phase I and Phase III Clinical Trial Application for Bevacizumab Biosimilar to Treat Cancer

SodaStream Builds Massive Marine Device to Collect Plastic Waste from the Ocean off the Coast of Honduras

Io-Tahoe campaigns for the Chief Data Officer (CDO) role to lead the data-driven business agenda

Central Park Tower, Tallest Residential Building In The World, Launches Sales

Huawei Launches Next-Generation SD-WAN Routers, Simplifying Cloud and Network Interconnection for Enterprises

Ewire Softtech Acquires Cashier Prepaid Cards

COA-TRC Selects AnantU to Host Heritage Documentation Training Programme

Avon Products Appoints New Vice President for IT Transformation

Neron Informatics Showcased its 3rd Telecom Innovation [N-50 UCS] in the 9th Edition of Aegis Graham Bell Awards 2018

Chitkara University Hosted India's Largest National Theatre Festival 'Rangrezz' 2018 on October 5-6, 2018

Adda52 Rummy Launches Vijaya Kaandam Rummy Tournament for Dusshera

Arla Foods Ingredients Acclaimed by Frost & Sullivan for its Osteopontin-enriched ingredient, Lacprodan® OPN-10

RailRestro Launches its Very own Food Delivery Fleet Brand - Railivery

e-Zest Mentioned in Gartner Digital Commerce Vendor Guide 2018

Sony Entertainment Television India (Sony TV) Launches Their First Official Movie Game With Aaryavarta Technologies for the Movie 'Namaste England'

Watch the Live Stream of Honor 8X India Launch on 16th October 2018 at 11:30 am IST

Huawei AI Fabric Raises Ethernet to a New Level of Ultra-High-Speed and Lossless Performance

Carsharing Operators Shorten their Go-to-Market Times Using Customisable Service-based Models

Verisign Presents DDoS Trends Report of Q2 2018

UBM India to Bring in the Maiden Edition of the Chennai Jewellery and Gem Fair

TalentSprint Hosts Confluence 2018, a Platform for Industry Academia Collaboration

Suning will actively participate in China International Import Expo

Clarivate Analytics Launches Cortellis CMC Intelligence to Expand Drug Availability in Low and Middle Income Countries

Indo-Australian Collaboration for Enhancing Community Media

Ex-Intel India CFO Joins INCX

StoutWeb Launches TraviYo to Help Travel Companies Manage Their Business Operations

Casio Launches Aviation Concept G-SHOCK Watch

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
BJP to fine tune strategies for three ma...
Congress ignored freedom fighters to pro...
Petrol pumps in Delhi to remain shut on ...
Man held on murder charges in Maharashtr...
Odisha Congress leader Padmalochan Panda...
Separatist shutdown, restrictions affect...
More...    
 
 Top Stories
Man held on murder charges in Mahar... 
Historic Jamia masjid closed again... 
Exams postponed in Kashmir... 
Kulgam blast: Case registered, inve... 
Karvan-e-Aman bus leaves for PoK... 
Train service suspended for securi... 
Jordan wants Israel to return borde... 
US peace plan to include Jerusalem ...